Here's Why We're Watching Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Here's Why We're Watching Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.
僅僅因為一家企業沒有賺到錢,並不意味著股票會下跌。例如,雖然亞馬遜上市後多年虧損,但如果你從1999年開始買入並持有股票,你就會發大財。但是,儘管成功是眾所周知的,但投資者不應忽視許多沒有盈利的公司,這些公司只是燒掉了所有的現金,然後倒閉。
So, the natural question for Kymera Therapeutics (NASDAQ:KYMR) shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.
所以,自然的問題是Kymera治療公司納斯達克(Sequoia Capital:KYMR)股東擔心的是,他們是否應該擔心其燒錢的速度。在這份報告中,我們將考慮該公司的年度自由現金流為負,此後將其稱為“現金消耗”。第一步是將它的現金消耗與其現金儲備進行比較,給我們提供它的“現金跑道”。
View our latest analysis for Kymera Therapeutics
查看我們對Kymera治療公司的最新分析
How Long Is Kymera Therapeutics' Cash Runway?
Kymera治療公司的現金跑道還有多長時間?
A company's cash runway is calculated by dividing its cash hoard by its cash burn. As at June 2023, Kymera Therapeutics had cash of US$368m and no debt. Importantly, its cash burn was US$169m over the trailing twelve months. That means it had a cash runway of about 2.2 years as of June 2023. That's decent, giving the company a couple years to develop its business. Depicted below, you can see how its cash holdings have changed over time.
一家公司的現金跑道是通過將其現金儲備除以現金消耗來計算的。截至2023年6月,Kymera Treeutics擁有3.68億美元現金,沒有債務。重要的是,在接下來的12個月裡,它的現金消耗為1.69億美元。這意味著,截至2023年6月,該公司的現金跑道壽命約為2.2年。這很不錯,給了公司幾年的時間來發展業務。如下所示,你可以看到它的現金持有量是如何隨著時間的推移而變化的。
![debt-equity-history-analysis](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231029/0-b682e93b52e235cffe981e89ae97f9c4-0-91f9a17767ceedea6517389bffefc6ad.png/big)
How Well Is Kymera Therapeutics Growing?
Kymera治療公司的發展情況如何?
Some investors might find it troubling that Kymera Therapeutics is actually increasing its cash burn, which is up 8.0% in the last year. And we must say we find it concerning that operating revenue dropped 8.9% over the same period. In light of the data above, we're fairly sanguine about the business growth trajectory. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.
一些投資者可能會發現令人擔憂的是,Kymera Treeutics實際上增加它的現金消耗,去年上漲了8.0%。我們必須說,我們發現同期營業收入下降了8.9%。根據上述數據,我們對業務增長軌跡相當樂觀。雖然過去總是值得研究的,但最重要的是未來。出於這個原因,看看我們分析師對該公司的預測是很有意義的。
Can Kymera Therapeutics Raise More Cash Easily?
Kymera Treateutics能輕鬆籌集更多現金嗎?
While Kymera Therapeutics seems to be in a fairly good position, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Many companies end up issuing new shares to fund future growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.
雖然Kymera治療公司似乎處於相當好的地位,但仍然值得考慮它如何輕鬆地籌集更多現金,即使只是為了推動更快的增長。發行新股或承擔債務是上市公司為其業務籌集更多資金的最常見方式。許多公司最終發行新股,為未來的增長提供資金。通過觀察一家公司相對於其市值的現金消耗,我們可以洞察到,如果公司需要籌集足夠的現金來支付另一年的現金消耗,股東將被稀釋多少。
Kymera Therapeutics has a market capitalisation of US$603m and burnt through US$169m last year, which is 28% of the company's market value. That's fairly notable cash burn, so if the company had to sell shares to cover the cost of another year's operations, shareholders would suffer some costly dilution.
Kymera治療公司的市值為6.03億美元,去年燒掉了1.69億美元,佔公司市值的28%。這是相當值得注意的現金消耗,因此,如果該公司不得不出售股票來彌補另一年的運營成本,股東將遭受一些代價高昂的稀釋。
Is Kymera Therapeutics' Cash Burn A Worry?
Kymera Treateutics的現金灼傷令人擔憂嗎?
Even though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought Kymera Therapeutics' cash runway was relatively promising. Even though we don't think it has a problem with its cash burn, the analysis we've done in this article does suggest that shareholders should give some careful thought to the potential cost of raising more money in the future. Taking an in-depth view of risks, we've identified 2 warning signs for Kymera Therapeutics that you should be aware of before investing.
儘管Kymera治療公司相對於其市值的現金消耗讓我們有點緊張,但我們不得不提到,我們認為Kymera治療公司的現金跑道相對有希望。儘管我們認為它的現金消耗沒有問題,但我們在本文中所做的分析確實表明,股東們應該仔細考慮未來籌集更多資金的潛在成本。深入分析風險,我們發現Kymera Treeutics的2個警告信號在投資之前你應該意識到這一點。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts)
當然了,如果你把目光投向別處,你可能會發現這是一筆很棒的投資。所以讓我們來看看這個免費內部人士正在買入的公司名單,以及這份名單中的成長股(根據分析師預測)
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫.或者,也可以給編輯組發電子郵件,地址是暗示Wallst.com。
本文由Simply Wall St.撰寫,具有概括性.我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議.它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況.我們的目標是為您帶來由基本面數據驅動的長期重點分析.請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內.Simply Wall St.對上述任何一隻股票都沒有持倉.